Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome

E-ISSN： 1873-4286|11|32|4177-4185

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.11, Iss.32, 2005-12, pp. : 4177-4185

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma

By Michels Judith Lassau Nathalie Gross-Goupil Marine Massard Christophe Mejean Arnaud Escudier Bernard

Investigational New Drugs, Vol. 28, Iss. 5, 2010-10 ,pp. : 690-693

Springer Publishing Company

Access to resources Recommend Favorite

Rasburicase

By Easton J. Noble S. Jarvis B.

Pediatric Drugs, Vol. 3, Iss. 6, 2001-01 ,pp. : 433-437

Adis International

Access to resources Recommend Favorite

Treating and Preventing Lung Cancer

By Winn Rodger J.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 2, 2004-03 ,pp. : 93-93

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

TACE inhibition: a new approach to treating inflammation

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 7, 2002-07 ,pp. : 1003-1006

Informa Healthcare

Access to resources Recommend Favorite

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome – 11β-hydroxysteroid dehydrogenase type 1

By Stewart Paul M

Clinical Medicine, Vol. 5, Iss. 2, 2005-03 ,pp. : 142-146

Royal College Of Physicians

Access to resources Recommend Favorite